NCT06988670View on ClinicalTrials.gov

A Phase 2 Trial Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults With Hypoparathyroidism

PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 5, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions
Hypoparathyroidism
Interventions
DRUG

EXT608

Modified version of parathyroid hormone attached to vitamin D to extend half-life

OTHER

Placebo

Placebo for injection

Trial Locations (1)

1180AAX

RECRUITING

Trial Site, Buenos Aires

Sponsors
All Listed Sponsors
lead

Extend Biosciences Inc.

INDUSTRY

NCT06988670 - A Phase 2 Trial Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults With Hypoparathyroidism | Biotech Hunter | Biotech Hunter